GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

The European stock markets closed mostly lower in Friday trading as The Stoxx Europe fell 0.49%, Germany's DAX dropped 0.58%, the FTSE in London was down 0.44%, France's CAC shed 1.51%, while the ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

EU Mid-Market Update: Traders primed to return with full force next week as January road ahead highlighted by Trumps return to office and beginning of Q4 earnings season; House Speaker vote in few ...

GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...

European stocks were poised for a second straight week of gains ahead of US manufacturing data that will provide clues on the ...

The FTSE 100 is expected to open flat on Friday, having closed up 1.1% on Thursday at 8,260.09.